OpenAI Acquires US AI Drug Development Platform Orchestra Bio to Bolster Rosalind Life Sciences Business
OpenAI announces the acquisition of Orchestra Bio to strengthen its life sciences product line, reflecting large model vendors' acceleration into vertical industry applications.
On October 21, OpenAI announced it has acquired Orchestra Bio, a US-based AI drug development collaboration platform, integrating its team and technology into its life sciences business, Rosalind. The transaction amount remains undisclosed as of publication.
Founded in 2022, Orchestra Bio provides R&D management software for biotech companies and pharmaceutical firms, helping teams plan research, manage budgets, and track project progress. Its founding team previously held early management roles at Benchling, a biotech R&D software company. By August 2025, the company had raised $20 million from investors including a16z, 8VC, and Insight Partners.
The acquisition aims to build agents capable of coordinating drug development, helping research teams translate findings into subsequent experiments, decisions, and actions. OpenAI noted that in the US, a new drug takes an average of 10 to 15 years from target discovery to approval, with dispersed information and interdependent steps increasing management complexity. Orchestra's agents can organize affected tasks and schedules, aggregating relevant information for scientists to make decisions.
Orchestra will be integrated into Rosalind, OpenAI's product system for life sciences research. In April this year, OpenAI released GPT-Rosalind, its first life-sciences-specific model, ending its research preview in September and starting billing on October 5. OpenAI stated it is collaborating with pharmaceutical companies such as Amgen, Moderna, and Novo Nordisk.
According to Crunchbase statistics, as of September 29, 2026, there have been 195 acquisitions of AI startups by VC-backed AI companies, exceeding the total for all of 2025. OpenAI alone has made 10 AI-related acquisitions this year. This trend indicates that competition among model vendors is extending from foundation model R&D to industry applications, aiming to capture professional market customers and budgets by acquiring specialized teams and software services.